



**Canadian Arthritis Network
International Partnership Initiative**

**International Research & Training Program
LABORATORY/CLINIC PROFILE**

Contact information of the principal investigator

Name:	John Esdaile
Dept and Institution:	Arthritis Research Centre of Canada Division of Rheumatology, University of British Columbia
Complete mailing address:	Arthritis Research Centre of Canada 895 W 10 th Ave Vancouver, BC V5Z 1L7
Phone:	604-871-4532
Email:	jesdaile@arthritisresearch.ca

Please indicate if you are member or affiliate of one or more of the following International Partnership Initiative organizations:

- AO Foundation – Biotechnology Advisory Board, Switzerland
- Arthritis Foundation, USA
- Arthritis Research Campaign, UK
- Canadian Arthritis Network, Canada
- Japan Society for the Promotion of Science, Japan
- Nuffield Foundation Oliver Bird Rheumatism Program, UK

International Research & Training Program Opportunity

Please indicate which of the following international opportunities would be available at your laboratory/clinic.

- Training Elective Rotation
- Research Mini-sabbatical
- Industry Training Rotation



The International Research & Training Program will be available for trainee elective rotations and investigator mini-sabbaticals that commence on or before March 31, 2009. If you have any preferences regarding the dates when you can host an international trainee or investigator, please indicate this below.

Visit Length (please indicate start and end dates if known):	To be discussed
---	-----------------

Please provide ten key words and a brief description of the research currently being conducted in your laboratory/clinic, including descriptions of any specialized equipment, methods or technologies employed at your facility.

10 key words

1. Clinical epidemiology
2. Health services/Models of care
3. Biostatistics
4. Knowledge translation
5. Cost studies
6. Quality of life
7. Pharmacology
8. Rheumatology
9. Orthopaedics
10. Rehabilitation sciences

Brief description (up to ½ page)

This centre focuses on clinical epidemiological and health services research, including health economic studies of arthritis, especially rheumatoid arthritis, seronegative arthritis and osteoarthritis. Examples of individual faculty interests include the psychosocial impact of rheumatoid arthritis (e.g. employment and work disability issues, parenting, and social support), risk factor analysis, and development of new measurement tools. There are close links to biomechanical engineering through the centre's participation in the Centre for Hip Health. The diverse scientific backgrounds of the faculty explain the highly collaborative research conducted at the centre. We are committed to "practical research for everyday living". To that end, the centre has appointed a Consumer Advisory Board, which collaborates actively on many studies, offering our scientists valuable insight into consumer needs and perspectives. For additional information on the Centre's faculty and activities, please see www.arthritisresearch.ca.

Key publications (maximum 5 publications)

1. Esdaile JM, Tannenbaum H, Hawkins D. Adult Still's disease. Am J Med 1980; 68: 825-830.
2. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994; 21: 2046-2051.



CANADIAN LE RÉSEAU
ARTHRITIS CANADIEN
NETWORK DE L'ARTHRITE

3. The Canadian Hydroxychloroquine Study Group (JM Esdaile, member). A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. *Lupus* 1998;7:80-85.
4. Esdaile, JE, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Cote R, Grover SA, Fortin PR, Clarke AE, Senecal J-L. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum* 2001;10:2331-7.
5. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, and The METGO Study Team. A 48-week, randomized, double-blind, double-observer, placebo-controlled trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis. *Arthritis Rheum* 2005;52:1360-1370.